Umckaloabo - NutraPedia

Back to Table of Contents

Umckaloabo Overview

1. Studied Conditions

Umckaloabo, derived from the roots of the South African plant Pelargonium sidoides, has been studied for several conditions. Notably, it has been researched for its effectiveness in treating acute bronchitis, the common cold, upper respiratory tract infections, and tonsillopharyngitis.

2. Efficacy in Treating Conditions

Some studies suggest that Umckaloabo may be effective in reducing the duration and severity of bronchitis symptoms, and it might help alleviate symptoms associated with the common cold. However, more research is needed to conclusively determine its efficacy, as results have been mixed and some studies have faced criticism regarding methodology.

3. Health Benefits

Umckaloabo is believed to offer several health benefits, including immune system support and anti-inflammatory properties. It may help relieve sore throat, cough, and nasal congestion. Its potential antibacterial and antiviral effects are also of interest, although these claims require further scientific validation.

4. Potential Downsides

While Umckaloabo is generally considered safe, it can have downsides. Potential side effects include gastrointestinal issues, such as nausea or diarrhea. Rarely, it may cause allergic reactions. Due to the lack of extensive research, long-term safety and all potential side effects may not be fully understood.

5. Genetic Variations and Umckaloabo

There is limited information on whether Umckaloabo is particularly beneficial or harmful for specific genetic variations. Personal genetic differences can influence how individuals metabolize and respond to herbal remedies, but targeted research on Umckaloabo and genetic variations is scarce. As such, it is essential to consult with a healthcare provider before using Umckaloabo, especially for individuals with known genetic susceptibilities or conditions.

Umckaloabo Research Summary

Overview

Umckaloabo is a phytopharmaceutical product derived from the roots of the plant Pelargonium sidoides. It is commonly used to treat respiratory tract infections such as acute bronchitis. Research on Umckaloabo has primarily focused on its efficacy, safety, and constituent components.

Main Constituents of EPs 7630

  • Oligomeric prodelphinidins
  • Carbohydrates, monomeric and oligomeric
  • Minerals
  • Peptides
  • Purine derivatives
  • Benzopyranones, including a disulfate of 6,7,8-trihydroxybenzopyranone

Effectiveness and Safety in Treating Acute Bronchitis

In clinical studies, Umckaloabo has shown to be more effective than placebo in treating acute bronchitis. It reduced bronchitis-specific symptom scores and was generally well-tolerated with mild to moderate side effects.

Antiviral and Immunomodulatory Effects

Umckaloabo offers antiviral and immune-modulating effects and has been evaluated in double-blind clinical trials. It has shown promising results in reducing cough, improving patient assessments, and shortening the duration of illness without significant side effects.

Efficacy in COPD Management

As an add-on therapy, Umckaloabo significantly prolonged the time to exacerbation in adults with stage II/III Chronic Obstructive Pulmonary Disease (COPD), demonstrating fewer exacerbations and improved quality of life.

Potential Allergic Reactions and Interactions

While Umckaloabo is generally considered safe, there have been case reports of allergic reactions suspected to be related to its use, particularly when used with anticoagulants or antiplatelet drugs.

Conclusion

Umckaloabo, derived from Pelargonium sidoides, has been supported by various studies to have a modest positive effect for patients with acute bronchitis, contributing to its use as an alternative to antibiotics in certain cases. Furthermore, its components and effects on the immune system suggest potential benefits in treating a variety of respiratory conditions.

References:


  1. Antibiotics for acute bronchitis
  2. Acute bronchitis
  3. A detailed view on the constituents of EPs 7630
  4. Neutrophils in the innate immune response
  5. Mucosal (secretory) immune system responses to exercise of varying intensity and during overtraining
  6. EPs 7630, an extract from Pelargonium sidoides roots inhibits adherence of Helicobacter pylori to gastric epithelial cells
  7. Efficacy and tolerability of EPs 7630 tablets in patients with acute bronchitis: a randomised, double-blind, placebo-controlled dose-finding study with a herbal drug preparation from Pelargonium sidoides
  8. EPs 7630-solution--an effective therapeutic option in acute and exacerbating bronchitis
  9. Randomised, double-blind, placebo-controlled trial of EPs 7630 in adults with COPD
  10. Mucosal immunity and respiratory illness in elite athletes
  11. Allergic reactions to medicines derived from Pelargonium species
  12. Fascinating metabolic pools of Pelargonium sidoides and Pelargonium reniforme, traditional and phytomedicinal sources of the herbal medicine Umckaloabo
  13. Synergistic Antimycobacterial Actions of Knowltonia vesicatoria (L.f) Sims
  14. Pelargonium sidoides for acute bronchitis: a systematic review and meta-analysis
  15. Evaluation of an aqueous-ethanolic extract from Pelargonium sidoides (EPs® 7630) for its activity against group A-streptococci adhesion to human HEp-2 epithelial cells
  16. Antibacterial activity of extracts and constituents of Pelargonium sidoides and Pelargonium reniforme
  17. Immunomodulatory principles of Pelargonium sidoides
  18. Pelargonium sidoides preparation (EPs 7630) in the treatment of acute bronchitis in adults and children
  19. Benzopyranones and their sulfate esters from Pelargonium sidoides
  20. Adverse drug reactions for CAM and conventional drugs detected in a network of physicians certified to prescribe CAM drugs
  21. Treatment of acute bronchitis with a liquid herbal drug preparation from Pelargonium sidoides (EPs 7630): a randomised, double-blind, placebo-controlled, multicentre study
  22. Mass spectroscopic characterisation of oligomeric proanthocyanidins derived from an extract of Pelargonium sidoides roots (EPs 7630) and pharmacological screening in CNS models
  23. Flow cytometric evaluation of adhesion of Streptococcus pyogenes to epithelial cells
  24. Evaluation of molecular chaperons Hsp72 and neuropeptide Y as characteristic markers of adaptogenic activity of plant extracts
  25. Investigation of the influence of EPs® 7630, a herbal drug preparation from Pelargonium sidoides, on replication of a broad panel of respiratory viruses
  26. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire
  27. Efficacy of a pelargonium sidoides preparation in patients with the common cold: a randomized, double blind, placebo-controlled clinical trial
  28. Efficacy and tolerability of EPs 7630 in patients (aged 6-18 years old) with acute bronchitis
  29. Anti-infective mode of action of EPs 7630 at the molecular level
  30. EPs® 7630 (Umckaloabo®), an extract from Pelargonium sidoides roots, exerts anti-influenza virus activity in vitro and in vivo
  31. Extract of Pelargonium sidoides (EPs 7630) improves phagocytosis, oxidative burst, and intracellular killing of human peripheral blood phagocytes in vitro
  32. Efficacy and safety of an extract of Pelargonium sidoides (EPs 7630) in adults with acute bronchitis. A randomised, double-blind, placebo-controlled trial
  33. Anti-infective activities of Pelargonium sidoides (EPS® 7630): effects of induced NO production on Leishmania major in infected macrophages and antiviral effects as assessed in a fibroblast-virus protection assay
  34. A historical, scientific and commercial perspective on the medicinal use of Pelargonium sidoides (Geraniaceae)
  35. Treatment of acute bronchitis with EPs 7630: randomized, controlled trial in children and adolescents
  36. EPs 7630 improves acute bronchitic symptoms and shortens time to remission. Results of a randomised, double-blind, placebo-controlled, multicentre trial
  37. Immune responses induced by Pelargonium sidoides extract in serum and nasal mucosa of athletes after exhaustive exercise: modulation of secretory IgA, IL-6 and IL-15
  38. Plant adaptogens. III. Earlier and more recent aspects and concepts on their mode of action
  39. Diagnosis and management of acute bronchitis
  40. Determination of umckalin in commercial tincture and phytopreparations containing Pelargonium sidoides by HPLC: comparison of sample preparation procedures
  41. Pharmacological profile of extracts of Pelargonium sidoides and their constituents
  42. The phenols and prodelphinidins of white clover flowers
  43. Components derived from Pelargonium stimulate macrophage killing of Mycobacterium species
  44. Can the Pelargonium sidoides root extract EPs® 7630 prevent asthma attacks during viral infections of the upper respiratory tract in children?
  45. Positioning of the Bronchitis Severity Score (BSS) for standardised use in clinical studies
  46. Treatment of the common cold in children and adults
  47. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary
  48. A broad review of commercially important southern African medicinal plants
  49. Treatment of rats with the Pelargonium sidoides extract EPs 7630 has no effect on blood coagulation parameters or on the pharmacokinetics of warfarin
  50. An extract of Pelargonium sidoides (EPs 7630) inhibits in situ adhesion of Helicobacter pylori to human stomach
  51. Anti-adhesive activities of flavan-3-ols and proanthocyanidins in the interaction of group A-streptococci and human epithelial cells
  52. Initially purported hepatotoxicity by Pelargonium sidoides: the dilemma of pharmacovigilance and proposals for improvement
  53. Treatment of acute bronchitis in adults with a pelargonium sidoides preparation (EPs 7630): a randomized, double-blind, placebo-controlled trial
  54. Large molecules as anti-adhesive compounds against pathogens
  55. Transient hypogammaglobulinemia and unclassified hypogammaglobulinemia: 'similarities and differences'
  56. Treatment of acute rhinosinusitis with the preparation from Pelargonium sidoides EPs 7630: a randomized, double-blind, placebo-controlled trial
  57. Conservation strategy for Pelargonium sidoides DC: phenolic profile and pharmacological activity of acclimatized plants derived from tissue culture
  58. Nitric oxide synthase and cytokines gene expression analyses in Leishmania-infected RAW 264.7 cells treated with an extract of Pelargonium sidoides (Eps 7630)
  59. New substances of plant origin which increase nonspecific resistance
  60. The efficacy of Pelargonium sidoides in the treatment of upper respiratory tract infections in children with transient hypogammaglobulinemia of infancy
  61. From cytokine to myokine: the emerging role of interleukin-6 in metabolic regulation
  62. Spontaneous reports of primarily suspected herbal hepatotoxicity by Pelargonium sidoides: was causality adequately ascertained?
  63. Genetic alterations for increased coumarin production lead to metabolic changes in the medicinally important Pelargonium sidoides DC (Geraniaceae)
  64. The spectrum of acute bronchitis. Using baseline factors to guide empirical therapy
  65. Efficacy of an aqueous Pelargonium sidoides extract against herpesvirus
  66. Extract of Pelargonium sidoides (EPs 7630) inhibits the interactions of group A-streptococci and host epithelia in vitro
  67. [Pelargonium sidoides - oral (Kaloban)]
  68. National Hospital Ambulatory Medical Care Survey: 1998 outpatient department summary
  69. Uncomplicated acute bronchitis


Upload Whole Genome Sequencing (WGS) raw DNA data today and take a deep dive into your genome!

Or if you only have standard microarray data currently, upload raw DNA data to get started with your free DNA raw data analysis today!